Predictive Factors for Silibinin Monotherapy in Patients With Chronic Hepatitis C and Nonresponse to PEG-IFN/RBV Therapy

被引：0
|
作者：
Rutter, Karoline
Stattermayer, Albert
Reiberger, Thomas
Aberle, Judith H.
Zinober, Kerstin
Scherzer, Thomas-Matthias
Beinhardt, Sandra
Holzmann, Heidemarie
Steindl-Munda, Petra
Hofer, Harald
Ferenci, Peter
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1257
引用
收藏
页码：S214 / S215
页数：2
相关论文
共 50 条
  • [31] PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C
    Ideo, G
    Giuseppe, S
    Attili, A
    Chirianni, A
    Craxi, A
    Di Perri, G
    Picciotto, A
    Rizzetto, M
    Ruggiero, G
    Suter, F
    Sarracino, M
    HEPATOLOGY, 2002, 36 (04) : 570A - 570A
  • [32] HCV-RNA and inflammasome is modulated by PEGylated interferon (PEG-IFNα-2b) monotherapy in chronic hepatitis c patients
    Manuela, G. Neuman
    Katz, Gadi G.
    Patel, Ankit
    Malkiewicz, M. Izabella
    Esguerra, Rustan
    CLINICAL BIOCHEMISTRY, 2010, 43 (09) : 781 - 781
  • [33] TREATMENT RESPONSE AND SAFETY OF PEG-IFN PLUS RIBAVIRIN THERAPY IN ELDERLY(≥65 YEARS) PATIENTS WITH CHRONIC HEPATITIS C
    Kim, In Hee
    Kim, Seong Hun
    Kim, Sang Wook
    Lee, Seung Ok
    Lee, Soo Teik
    Kim, Dae Ghon
    HEPATOLOGY, 2011, 54 : 874A - 874A
  • [34] IL28B genetic variants and serum IP-10 level associated with virological response to PEG-IFN/RBV and PEG-IFN/RBV/Telaprevir therapy
    Matsuura, Kentaro
    Tanaka, Yasuhito
    Watanabe, Tsunamasa
    Murakami, Shuko
    Iio, Etsuko
    Endo, Mio
    Shinkai, Noboru
    Fujiwara, Kei
    Miyaki, Tomokatsu
    Nojiri, Shunsuke
    Kusakabe, Atsunori
    Orito, Etsuro
    Joh, Takashi
    Mizokami, Masashi
    HEPATOLOGY, 2012, 56 : 998A - 999A
  • [35] Current status of subjects receiving Peg-Interferon-alfa-2A (Peg-IFN) and ribavirin (RBV) follow-on therapy after 28-day treatment with the hepatitis C protease inhibitor telaprevir (VX-950), Peg-IFN and RBV
    Rodriguez-Torres, Maribel
    Lawitz, Eric
    Muir, Andrew
    Keane, James
    Kieffer, Tara
    McNair, Lindsay
    McHutchison, John G.
    HEPATOLOGY, 2006, 44 (04) : 532A - 532A
  • [36] ANTIGEN PROCESSING AND PROTEASOME DEGRADATION PATHWAYS ARE INVOLVED IN PATIENTS WITH CHRONIC HEPATITIS C WITH NEGATIVE PREDICTORS OF RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN (PEG-IFN/RBV)
    Birerdinc, A.
    Afendy, A.
    Stepanova, M.
    Younossi, I.
    Manyam, G.
    Baranova, A.
    Younossi, Z.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S471 - S471
  • [37] Erythropoictic response to anemia is decreased in patients infected with hepatitis C virus (HCV) receiving combination ribavirin and pegylated interferon (RBV/PEG-IFN) therapy
    Balan, V
    Wu, GY
    Muir, AJ
    Keeffe, EB
    Bowers, PJ
    GASTROENTEROLOGY, 2003, 124 (04) : A751 - A751
  • [38] Utility of agora criteria in the decision to re-treat patients with Hepatitis C and failure of previous treatment with peg-ifn and RBV
    Sola, Ricard
    Diago, Moises
    Crespo, Javier
    Dalmau, Blai
    Morillas, Rosa Maria
    Suarez, Dolores
    Bonet, Lucia
    Montoliu, Silvia
    Xavier Cervantes, Francesc
    Planas, Ramon
    Garcia-Samaniego, Javier
    Romero-Gomez, Manuel
    Calleja, Jose L.
    HEPATOLOGY, 2012, 56 : 664A - 664A
  • [39] Prospective assessment of the incidence of infections during pegylated interferon (PEG-IFN) plus ribavirin (RBV) treatment for chronic hepatitis C (CHC)
    Zuin, M
    Giorgini, A
    Battezzati, PM
    Lleo, A
    Cardani, F
    Podda, M
    HEPATOLOGY, 2004, 40 (04) : 329A - 329A
  • [40] Genetic Variation in Interleukin-28B and Response to Peg-IFNα-2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection
    Bokharaei-Salim, Farah
    Salehi-Vaziri, Mostafa
    Sadeghi, Farzin
    Khanaliha, Khadijeh
    Esghaei, Maryam
    Monavari, Seyed Hamidreza
    Alavian, Seyed Moayed
    Fakhim, Shahin
    Keyvani, Hossein
    JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 2017, 10 (01)
12345